Achmea Investment Management B.V. raised its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 52.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,746 shares of the biotechnology company's stock after purchasing an additional 12,627 shares during the quarter. Achmea Investment Management B.V. owned about 0.08% of United Therapeutics worth $12,965,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Vestcor Inc lifted its holdings in shares of United Therapeutics by 40.7% during the 4th quarter. Vestcor Inc now owns 1,413 shares of the biotechnology company's stock valued at $499,000 after acquiring an additional 409 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of United Therapeutics by 32.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,532 shares of the biotechnology company's stock valued at $5,127,000 after acquiring an additional 3,573 shares in the last quarter. Avantax Advisory Services Inc. acquired a new position in shares of United Therapeutics during the 4th quarter valued at $209,000. Great Lakes Advisors LLC lifted its holdings in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after acquiring an additional 31 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of United Therapeutics by 18.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 853 shares of the biotechnology company's stock valued at $301,000 after acquiring an additional 130 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on UTHR shares. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.
View Our Latest Research Report on UTHR
Insider Activity at United Therapeutics
In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of the business's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares of the company's stock, valued at $1,885,134.22. The trade was a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 255 shares of the business's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company's stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 116,464 shares of company stock valued at $42,396,244 in the last quarter. Insiders own 11.90% of the company's stock.
United Therapeutics Stock Up 0.6 %
Shares of UTHR traded up $1.85 during midday trading on Friday, hitting $307.24. The company had a trading volume of 494,807 shares, compared to its average volume of 445,927. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The company's 50 day moving average price is $349.77 and its 200 day moving average price is $358.48. The stock has a market cap of $13.80 billion, a price-to-earnings ratio of 13.49, a PEG ratio of 0.97 and a beta of 0.64.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the prior year, the firm earned $4.36 EPS. Equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.
United Therapeutics Profile
(
Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also

Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.